At present, there are no FDA-approved anti-BRAF drugs; however, combinations of selective RAF and EGFR inhibitors have shown encouraging initial results and the National Comprehensive Cancer Network recommend a combination of RAF inhibitor vemurafenib with cetuximab and the chemotherapy agent irinotecan for BRAF V600E-mutated CRC owing to its improved progression-free survival compared with regimens without RAF inhibition (118). The gene discussed is BRAF; the disease is colorectal carcinoma.